- Home
- MCRB vs PLCE Comparison
MCRB vs PLCE Comparison
Compare MCRB & PLCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- PLCE
- Stock Information
- Founded
- MCRB 2010
- PLCE 1969
- Country
- MCRB United States
- PLCE United States
- Employees
- MCRB N/A
- PLCE N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- PLCE Clothing/Shoe/Accessory Stores
- Sector
- MCRB Health Care
- PLCE Consumer Discretionary
- Exchange
- MCRB Nasdaq
- PLCE Nasdaq
- Market Cap
- MCRB 144.6M
- PLCE 169.6M
- IPO Year
- MCRB 2015
- PLCE 1997
- Fundamental
- Price
- MCRB $17.75
- PLCE $8.20
- Analyst Decision
- MCRB Hold
- PLCE Hold
- Analyst Count
- MCRB 4
- PLCE 1
- Target Price
- MCRB $14.33
- PLCE $7.00
- AVG Volume (30 Days)
- MCRB 101.5K
- PLCE 555.6K
- Earning Date
- MCRB 11-12-2025
- PLCE 12-02-2025
- Dividend Yield
- MCRB N/A
- PLCE N/A
- EPS Growth
- MCRB N/A
- PLCE N/A
- EPS
- MCRB 10.22
- PLCE N/A
- Revenue
- MCRB N/A
- PLCE $1,338,867,000.00
- Revenue This Year
- MCRB N/A
- PLCE N/A
- Revenue Next Year
- MCRB N/A
- PLCE $0.68
- P/E Ratio
- MCRB $1.74
- PLCE N/A
- Revenue Growth
- MCRB N/A
- PLCE N/A
- 52 Week Low
- MCRB $6.53
- PLCE $3.66
- 52 Week High
- MCRB $24.67
- PLCE $17.19
- Technical
- Relative Strength Index (RSI)
- MCRB 42.40
- PLCE 61.99
- Support Level
- MCRB $17.63
- PLCE $7.10
- Resistance Level
- MCRB $19.30
- PLCE $8.92
- Average True Range (ATR)
- MCRB 1.12
- PLCE 0.68
- MACD
- MCRB -0.29
- PLCE 0.02
- Stochastic Oscillator
- MCRB 5.42
- PLCE 62.88
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.